OBX (Obsidian Therapeutics) 12-1 Month Momentum %: N/A% (As of Sep. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OBX Obsidian Therapeutics Inc OBX
11 GF Score
Price $17.50
! 1 Warning Sign
View Full Analysis

What is Obsidian Therapeutics 12-1 Month Momentum %?

Obsidian Therapeutics OBX +0.98% 11 12-1 Month Momentum % is N/A% as of Sep. 22, 2026. GuruFocus rates OBX with a GF Score™ of 11/100. The stock has 1 warning sign investors should review. Among 1,352 Biotechnology companies, Obsidian Therapeutics ranks worse than 73964.42% on this metric.

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-09-22), Obsidian Therapeutics's 12-1 Month Momentum % is N/A%.

The industry rank for Obsidian Therapeutics's 12-1 Month Momentum % or its related term are showing as below:

OBX's 12-1 Month Momentum % is not ranked *
in the Biotechnology industry.
Industry Median: -20.52
* Ranked among companies with meaningful 12-1 Month Momentum % only.

Obsidian Therapeutics  (NAS:OBX) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Obsidian Therapeutics 12-1 Month Momentum % Related Terms

OBX
11GF Score
Obsidian Therapeutics Inc OBX
12-1 Month Momentum % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Obsidian Therapeutics  (NAS:OBX) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 12-1 Month Momentum % →
What does a 12-1 Month Momentum % of N/A% mean?
Obsidian Therapeutics (OBX) has a 12-1 Month Momentum % of N/A% as of Sep. 22, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Obsidian Therapeutics and its competitors. According to the industry distribution chart, Obsidian Therapeutics ranks #999999 out of 1352 companies in the Biotechnology industry.
Is Obsidian Therapeutics' 12-1 Month Momentum % too high?
Obsidian Therapeutics' current 12-1 Month Momentum % is N/A%. Based on the distribution chart, Obsidian Therapeutics ranks #999999 out of 1352 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Obsidian Therapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Obsidian Therapeutics' 12-1 Month Momentum % compare to LXRX and SLNCF?
According to the Biotechnology industry distribution chart, Obsidian Therapeutics ranks #999999 out of 1352 companies for 12-1 Month Momentum %. This places Obsidian Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Biotechnology company?
A good 12-1 Month Momentum % depends on the Biotechnology industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Obsidian Therapeutics and its competitors. Obsidian Therapeutics's current 12-1 Month Momentum % is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Obsidian Therapeutics stock overvalued right now?
Obsidian Therapeutics (OBX) has a current 12-1 Month Momentum % of N/A%. The current 12-1 Month Momentum % is N/A%. Obsidian Therapeutics' overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For Obsidian Therapeutics (OBX), the current 12-1 Month Momentum % is N/A% as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Obsidian Therapeutics Business Description

Address 1030 Massachusetts Avenue, Suite 400, Cambridge, MA, USA, 02138
Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocytes (TIL) cell therapies for the treatment of patients with solid tumors. The company's proprietary cytoDRiVE platform is versatile and allows it to leverage drug responsive domains to control protein function, with its initial focus on TIL cell therapies developed from this platform (cytoTILs). The company's flagship product candidate, OBX-115, is a novel, genetically engineered, autologous TIL cell therapy currently in a Phase 2 clinical trial for the treatment of melanoma and a Phase 1 clinical trial for the treatment of non-small cell lung cancer.
11GF Score

Get the complete analysis for OBX

12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.50
Price